Sub Investigator

  1. ALIFTUS Trial: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma INVESTIGATIONAL NEW DRUG PROTOCOL AL3818 (ANLOTINIB, INN: CATEQUENTINIB) HYDROCHLORIDE PROTOCOL NUMBER: AL3818-US-002 ADVENCHEN LABORATORIES, LLC

  2. KEYNOTE-C93/GOG-3064/ENGOT-en15 Protocol Title: A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15) Protocol Number: C93-02/GOG-3064/ENGOT-en15 ; Sponsor -MSD

  3. ARTISTRY-7 TRIAL: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

  4. ATARI Trial: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss; ENGOT-GYN1/NCRI/ATARI The Institute of Cancer Research Funders: AstraZeneca Lady Garden Foundation Coordinating Trials Unit: ICR Clinical Trials and Statistics Unit (ICR-CTSU) The Institute of Cancer Research

  5. ATTEND Trial: PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL OF ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER (Atezolizumab Trial in Endometrial cancer – AtTEnd; PROTOCOL NUMBER: IRFMN-EN-7556; SPONSOR Mario Negri Gynecology Oncology Group (MaNGO) – Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano

  6. CEBOC Trial: Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer; Phase II; AstraZeneca (AZ) Reference ESR-15-11304 ISRCTN38690336.

  7. COMICE Trial: A randomised double-blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer (COMICE); ISRCTN number: 10841582; Study Sponsor / Co-sponsors: The Clatterbridge Cancer Centre NHS Foundation Trust EudraCT number: 2016-004215-13 ISRCTN number: 10841582.

  8. COPELIA trial: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for disease relapse within 18 months of adjuvant carboplatin-paclitaxel chemotherapy. V6.0(27OCT2021); AstraZeneca; ISRCTN16320634

  9. CRAIN trial: A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer; SPONSOR: University Hospital Southampton NHS Foundation Trust (UHS); ISRCTN reference: 18574865.

  10. DICE trial: An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma). DICE Trial: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma)

  11. EPIK-O Trial: A Phase III, multi-center, randomized (1:1), openlabel, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer; EUDRACT number: 2019-004682-40; Novartis.

  12. ICON-9 Trial: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy Trial Sponsor: University College London Trial Sponsor reference: UCL/14/0795 Clinicaltrials.gov no: NCT03278717 EUDRACT no: 2017-000161-75.

  13. MIRASOL Trial: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in PlatinumResistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression Study Number: IMGN853-04; Sponsor: ImmunoGen, Inc.

  14. KEYNOTE-B21 / ENGOT-en11 / GOG-3053 Trial: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053). Protocol Number: B21-03 / ENGOT-en11 / GOG-3053; MSD

  15. MORAb-202-G000-201 Trial: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types; Eisai Inc; EudraCT Number: 2019-003600-12

  16. PEACOCC Trial: A phase II study of PEmbrolizumab in patients with Advanced gynaeCOlogical Clear Cell Cancer Trial Sponsor: University College London Trial Sponsor reference: UCL/17/0672 Trial funder: Merck Sharp & Dohme (MSD) Limited MSD reference: MISP 55357 Clinicaltrials.gov no: NCT03425565 EUDRACT no: 2017-004168-36

  17. ACTOv Trial: Adaptive ChemoTherapy for Ovarian cancer: A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer Trial Sponsor: University College London Trial Sponsor reference: UCL136618 Trial funders: Barts Charity Anticancer Fund Funders reference: Barts Charity: MGU0598 ACF: RCT-A80-2021 Clinicaltrials.gov no: NCT05080556 EUDRACT no: 2021-003412-40

  18. R4018-ONC-1721 clinical trial: A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer Compound: REGN4018; Protocol Number: R4018-ONC-1721; EudraCT Number: 2019-003298-24 IND Number: 134785 Regeneron Pharmaceuticals, Inc

  19. RAMP trial: A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201); VS-6766-201 (Verastem, Inc) ENGOT-ov60/NCRI (European Network for Gynaecological Oncological Trial groups) GOG-3052 (The GOG Foundation); EudraCT Number: 2020-004264-26

  20. ROSY-O Trial: A Master, Roll Over StudY for Patients Who Have Completed a Previous Oncology Study and Are Judged by the Investigator to Clinically Benefit From Continued Treatment TITLE PAGE Sponsor: AstraZeneca AB

  21. PAIRS Trial: PARP Inhibitor Resistance Study; ISRCTN No: 59698923 Protocol No: PAIRS-2021 IRAS No: 297051; Sponsor: NHS Greater Glasgow & Clyde

  22. SGNTV-003 trial: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Secondor Third-Line Recurrent or Metastatic Cervical Cancer; Seagen Inc.; EudraCT No.: 2019-001655-39; ENGOT Study No. ENGOT-cx12

  23. SKYSCRAPPER Trial: A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1−POSITIVE CERVICAL CANCER PROTOCOL NUMBER: WO42017 VERSION NUMBER: 7 EUDRACT NUMBER: 2019-004895-21; SPONSOR: F. Hoffmann-La Roche Ltd.

  24. SL03-OHD-105 Trial: An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers; Shattuck Labs, Inc; EudraCT: 2022-000698-17

  25. VALTIVE 1 Trial: VALIDATION OF TIE2 AS THE FIRST TUMOUR VASCULAR RESPONSE BIOMARKER FOR VEGF INHIBITORS: OPTIMISING THE DESIGN OF A SUBSEQUENT RANDOMISED DISCONTINUATION TRIAL: VALTIVE1; Sponsor: The University of Manchester; Funder: CRUK; IRAS number: 285116 ClinicalTrials.gov ref: NCT0452311